Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa  C.E. Wainwright, A.L. Quittner, D.E. Geller, C. Nakamura, J.L. Wooldridge, R.L. Gibson, S. Lewis, A.B. Montgomery  Journal of Cystic Fibrosis  Volume 10, Issue 4, Pages 234-242 (July 2011) DOI: 10.1016/j.jcf.2011.02.007 Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Patient disposition. Journal of Cystic Fibrosis 2011 10, 234-242DOI: (10.1016/j.jcf.2011.02.007) Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Key efficacy endpoints. Mean changes in CFQ-R Respiratory Symptoms Scores (in points, on a scale of 0–100), mean relative changes in FEV1% predicted (percentage change from baseline values), and changes in log10 PA CFU/g sputum are plotted across the study visits. Journal of Cystic Fibrosis 2011 10, 234-242DOI: (10.1016/j.jcf.2011.02.007) Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Four-fold or greater changes in minimum inhibitory concentrations (MICs) of aztreonam for P. aeruginosa (PA). Each horizontal bar represents data from a single patient. The left and right ends of a bar denote the aztreonam MIC of the least susceptible PA isolate at baseline and Day 28, respectively. Data are shown for all patients with ≥4-fold increases in aztreonam MIC values from baseline to Day 28. The vertical dotted line represents the parenteral susceptibility breakpoint of aztreonam for PA (8μg/mL). Patients with MIC data: AZLI (N=44), placebo (N=54). Journal of Cystic Fibrosis 2011 10, 234-242DOI: (10.1016/j.jcf.2011.02.007) Copyright © 2011 European Cystic Fibrosis Society. Terms and Conditions